Rightslink® by Copyright Clearance Center

Treatment inequities in newly diagnosed diffuse large B-cell lymphoma (DLBCL): Comparing polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisone (Pola-R-CHP) vs rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) among Medicare beneficiaries

Author:

John Vaughn,Anthony Masaquel,Carolina Reyes,Farah Hossain,Eric Zuk,Rebecca Straubing,Matthew Davis,Scott Huntington

Publication:

Blood

Publisher:

Elsevier

Date:

3 November 2025

Copyright © 2025 American Society of Hematology. Published by Elsevier Inc. All rights reserved. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Please select your organization and/or account

Organization

Account

Please select your account from the above dropdown list. These accounts represent the offices, campuses, and other sites where your organization operates. Your account selection should match where you typically have an office or workspace. Even when you are traveling or temporarily working elsewhere, you should select the account that represents where you customarily work.

Cancel OK

Content Excluded

This content has been excluded from the RightsLink's service. Please contact Elsevier directly with your request.